Exane Derivatives’s Intercept Pharmaceuticals, Inc. ICPT Stock Holding History

Exane Derivatives’s Portfolio ICPT Stock Details ICPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	$83	Hold	6	–	–	﹤0.01%	723
2022 Q1	$98	Hold	6	–	–	﹤0.01%	991
2021 Q4	$98	Hold	6	–	–	﹤0.01%	860
2021 Q3	$89	Hold	6	–	–	﹤0.01%	1027
2021 Q2	$105	Hold	6	–	–	﹤0.01%	1028
2021 Q1	$138	Hold	6	–	–	﹤0.01%	859
2020 Q4	$148	Hold	6	–	–	﹤0.01%	804
2020 Q3	$249	Hold	6	–	–	﹤0.01%	717
2020 Q2	$287	Hold	6	–	–	﹤0.01%	644
2020 Q1	$378	Hold	6	–	–	﹤0.01%	624
2019 Q4	$677	Sell	6 -3,781	-100%	-$339K	﹤0.01%	581
2019 Q3	$251K	Hold	3,787	–	–	0.05%	216
2019 Q2	$301K	Buy	3,787 +3,781	+63,017%	+$338K	0.05%	221
2019 Q1	$671	Hold	6	–	–	﹤0.01%	525
2018 Q4	$605	Sell	6 -1	-14%	-$104	﹤0.01%	599
2018 Q3	$884	Hold	7	–	–	﹤0.01%	549
2018 Q2	$588	Hold	7	–	–	﹤0.01%	559
2018 Q1	$414	Sell	7 -943	-99%	-$56.8K	﹤0.01%	518
2017 Q4	$55.5K	Sell	950 -4,127	-81%	-$260K	0.01%	333
2017 Q3	$295K	Buy	5,077 +5,066	+46,055%	+$546K	0.06%	172
2017 Q2	$1.33K	Buy	+11	New	+$1.27K	﹤0.01%	463

Other funds holding ICPT

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $23.2B AUM 40.19% 1-Year Est. Return

Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return

Rockefeller Capital Management New York $65.2B AUM 31.44% 1-Year Est. Return

Exane Derivatives's ICPT Position: Q2 2022 in Review

Exane Derivatives held its Intercept Pharmaceuticals, Inc. (ICPT) position steady in Q2 2022 at 6 shares worth $83. The position accounts for ﹤0.01% of the portfolio, ranked #723.

Exane Derivatives first reported a position in ICPT in Q2 2017 and has held it in 21 quarters since. The position peaked at $301K in Q2 2019. 144 funds tracked by Wall St. Rank hold ICPT as of Q2 2022.

Exane Derivatives held 6 shares of Intercept Pharmaceuticals, Inc. worth $83 as of Q2 2022.
Exane Derivatives left its Intercept Pharmaceuticals, Inc. share count unchanged in Q2 2022.
Intercept Pharmaceuticals, Inc. made up ﹤0.01% of Exane Derivatives's portfolio in Q2 2022, its #723 holding.
Exane Derivatives first reported a position in Intercept Pharmaceuticals, Inc. in Q2 2017 and has held it in 21 quarters since.
Exane Derivatives's Intercept Pharmaceuticals, Inc. position peaked at $301K in Q2 2019.
144 funds tracked by Wall St. Rank held Intercept Pharmaceuticals, Inc. as of Q2 2022.

Based on Exane Derivatives's 13F filing for Q2 2022, filed 12 Jul 2022.